Wednesday, November 21, 2012

• Stocks for the Long Run: AstraZeneca vs. the FTSE 100at Motley Fool (Wed, Nov 21)

Tuesday, November 20, 2012

• 3 Things to Watch With Nektar Therapeuticsat Motley Fool (Tue, Nov 20)
• Waiting For Fiscal Cliff Fallout Isn't 'Market Timing'at Seeking Alpha (Tue, Nov 20)

Monday, November 19, 2012

• Could A Fish Oil Backlash Wash Out Amarin Pharmaceuticals?at Forbes (Mon, Nov 19)
• GlaxoSmithKline Could Sink on Recent Eventsat Motley Fool (Mon, Nov 19)

Sunday, November 18, 2012

• Biotech Weekend Recap: Frustration And Disastersat Seeking Alpha (Sun, Nov 18)

Saturday, November 17, 2012

• 5%+ Dividend Payers From Europeat Seeking Alpha (Sat, Nov 17)

Friday, November 16, 2012

• No News Equals Bad News for Amarin Investorsat Motley Fool (Fri, Nov 16)
• Amarin Pushed Closer to Solo Vascepa Launch By Another NCE Delayat TheStreet (Fri, Nov 16)
• AstraZeneca PLC (AZN): Today's Featured Drugs Laggardat TheStreet (Fri, Nov 16)
• Is Vivus a Buy with Obesity on the Rise?at Wall St. Cheat Sheet (Fri, Nov 16)
• Investors Still Waiting for Decision on Amarin Fish-Oil Drug Exclusivityat Minyanville (Fri, Nov 16)
• 5 Stocks Pushing The Drugs Industry Lowerat TheStreet (Fri, Nov 16)
• Dynavax plunges 50 percent on Heplisav panel voteAP (Fri, Nov 16)
• Forxiga For Type 2 Diabetes Is A Potential Blockbuster - Buy AstraZenecaat Seeking Alpha (Fri, Nov 16)
• ArcelorMittal Divests Stake, Multiple Bidders Possible for Amarin: Merger and Acquisitions Updateat Wall St. Cheat Sheet (Fri, Nov 16)

Thursday, November 15, 2012

• A New Player in the Amarin Buyout Saga?at Motley Fool (Thu, Nov 15)
• The Winners And Losers Of QE3at Investopedia (Thu, Nov 15)
• AZN's Forxiga Gets EU ApprovalZacks (Thu, Nov 15)
• AZ&Me™ Prescription Savings Program for People with Medicare Part D Removes Out-of-Pocket Spend RequirementBusiness Wire (Thu, Nov 15)
• Calcalist: Teva is leading candidate to buy Amarin, Reuters reportsat theflyonthewall.com (Thu, Nov 15)

Wednesday, November 14, 2012

• Can You Double Your Money with Dynavax?at Motley Fool (Wed, Nov 14)
• Who Will Pioneer the New Diabetes Market?at Motley Fool (Wed, Nov 14)
• 3 Potential Partners for Amarinat Motley Fool (Wed, Nov 14)
• Teva Is Still Healthier Than Its Big Pharma Peersat Seeking Alpha (Wed, Nov 14)

Add AZN News to My Yahoo!